Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4.66% | 13.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.66% | 13.86% | |||
| Cost of Revenue | 2.03% | 17.00% | |||
| Gross Profit | 6.23% | 12.05% | |||
| SG&A Expenses | 36.13% | -26.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.78% | -8.19% | |||
| Operating Income | -32.89% | 343.88% | |||
| Income Before Tax | -30.10% | 298.51% | |||
| Income Tax Expenses | -44.92% | -- | |||
| Earnings from Continuing Operations | -29.47% | 282.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.47% | 282.27% | |||
| EBIT | -32.89% | 343.88% | |||
| EBITDA | -31.96% | 304.66% | |||
| EPS Basic | -30.23% | 277.73% | |||
| Normalized Basic EPS | -30.92% | 294.81% | |||
| EPS Diluted | -30.56% | 332.00% | |||
| Normalized Diluted EPS | -31.41% | 279.47% | |||
| Average Basic Shares Outstanding | 1.12% | 1.28% | |||
| Average Diluted Shares Outstanding | 1.90% | 5.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||